Home > Insider Trading > Filing (0000899243-17-009070)

Filing Details

Accession Number:: 0000899243-17-009070
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-31 21:30:30
Reporting Period:: 2017-03-15

Filing Date:: 2017-03-31
Accepted Time:: 2017-03-31 21:30:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1103021	Biodelivery Sciences International Inc	BDSI	Pharmaceutical Preparations (2834)	352089858

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1301715	A Mark Sirgo	C/O Biodelivery Sciences Intl, Inc., 4131 Parklake Avenue, Suite 225 Raleigh NC 27612	President, Ceo & Vice Chairman	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-03-15	524,418	$0.00	1,670,157	No	4	A	Direct
Common Stock	Disposition	2017-03-23	1,795	$1.90	1,668,362	No	4	S	Direct
Common Stock	Disposition	2017-03-27	32,000	$1.88	1,636,362	No	4	S	Direct
Common Stock	Disposition	2017-03-28	49,500	$1.90	1,586,862	No	4	S	Direct
Common Stock	Disposition	2017-03-30	12,500	$1.86	1,574,362	No	4	S	Direct
Common Stock	Disposition	2017-03-31	15,100	$1.99	1,559,262	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2017-03-15	524,418	$0.00	524,418	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
630,170	2017-03-15	2017-03-15	No	4	A	Direct

Footnotes

The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") as follows: (i) 15,888 shares of common stock were granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017; (ii) 140,000 shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on March 15, 2017; (iii) 96,837 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remaining half of the RSUs under this grant will vest on September 13
(Continued from footnote 1) ; (iv) 266,667 shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on March 15, 2017. Pursuant to a deferral, the remainder of the RSUs under this grant will vest in equal portions on each of (a) September 14, 2017 and (b) February 23, 2018; and (v) 5,026 shares of common stock reported on this Form 4 became exercisable on March 21, 2017 and were acquired by the Reporting Person on March 22, 2017 in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.
The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
On March 27, 2017, the Reporting Person sold an aggregate of 32,000 shares of the Issuer's Common Stock at a weighted average price of $1.88 per share. The highest sale price for the Common Stock was $1.90 per share and the lowest sale price was $1.88 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On March 28, 2017, the Reporting Person sold an aggregate of 49,500 shares of the Issuer's Common Stock at a weighted average price of $1.90 per share. The highest sale price for the Common Stock was $1.93 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On March 30, 2017, the Reporting Person sold an aggregate of 12,500 shares of the Issuer's Common Stock at a weighted average price of $1.86 per share. The highest sale price for the Common Stock was $1.88 per share and the lowest sale price was $1.86 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On March 31, 2017, the Reporting Person sold an aggregate of 15,100 shares of the Issuer's Common Stock at a weighted average price of $1.99 per share. The highest sale price for the Common Stock was $2.03 per share and the lowest sale price was $1.93 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.